BioCentury
ARTICLE | Clinical News

AGT-182: Phase I/IIa data

August 1, 2016 7:00 AM UTC

Data from the first cohort of 4 Hunter syndrome patients ages >=18 in the open-label, international Phase I/IIa Breaking Barriers trial showed that once-weekly 1 mg/kg IV AGT-182 for 8 weeks was gener...